CNS seniors ride again as Merck KGaA strikes new Newron deal
This article was originally published in Scrip
Executive Summary
Newron Pharmaceuticals has received a development licence for two compounds, broadening the scope of its collaboration with Merck Serono (Merck KGaA). The two companies are already collaborating on the development of safinamide in Parkinson's disease.